Jci_page_head_homepage_01 Jci_page_head_homepage_02
Xabier L. Aranguren, Jonathan D. McCue, Benoit Hendrickx, Xiao-Hong Zhu, Fei Du, Eleanor Chen, Beatriz Pelacho, Ivan Peñuelas, Gloria Abizanda, Maialen Uriz, Sarah A. Frommer, Jeffrey J. Ross, Betsy A. Schroeder, Meredith S. Seaborn, Joshua R. Adney, Julianna Hagenbrock, Nathan H. Harris, Yi Zhang, Xiaoliang Zhang, Molly H. Nelson-Holte, Yuehua Jiang, An D. Billiau, Wei Chen, Felipe Prósper, Catherine M. Verfaillie, Aernout Luttun
Published in Volume 118, Issue 2
J Clin Invest. 2008; 118(2):505–514 doi:10.1172/JCI31153
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 4
Late effects of mMAPC-U, mMAPC-VP, and mBMCs in moderate ischemia.

(A) Laser Doppler measurements in left legs (expressed as % of the nonligated right leg) of vehicle- (red), mMAPC-U– (black), mBMC- (gray), or mMAPC-VP–treated mice (blue). (B) Swim performance (expressed as % versus day –1 [baseline]) of vehicle- (red), mMAPC-U– (black), mBMC- (gray), or mMAPC-VP–treated mice (blue). (C) Table summarizing clinical evaluation of all treatment regimens up to 5 weeks after transplantation. Representative images (DG) and corresponding quantification (H) of whole-tissue (gastrocnemius muscle, cut into 2 slices of equal thickness) viability (red, viable tissue) by triphenyltetrazolium chloride (TTC) staining 4 weeks after transplantation in vehicle (D; red in H), mMAPC-U (E; black in H), mBMC (F; gray in H), and mMAPC-VP (G; blue in H) groups. (IL) Sirius red–stained cross sections of gastrocnemius muscle 5 weeks after transplantation of vehicle- (I), mMAPC-U– (J), mBMC- (K), or mMAPC-VP–injected (L) animals. All analyses were performed on 6–12 mice per group. The insets in E and J show a nonischemic muscle. *P < 0.05 versus vehicle for each corresponding time point. Scale bars: 500 μm (IL). Original magnification, ×2 (DG); ×0.66 (inset E); ×2.5 (inset J).